Updated:
China Pharma Holdings
China Pharma Holdings develops and sells generic drugs to Chinese hospitals from its GMP-certified facility in Hainan.
China Pharma Holdings
China Pharma Holdings, Inc. conducts its business through wholly owned subsidiaries in the People's Republic of China, focusing on the development, manufacture, and marketing of generic and Western-medicine-based pharmaceutical products. The company targets high-incidence, high-mortality conditions and maintains a pipeline spanning central nervous system disorders, cardiovascular diseases, and infectious diseases. Its products are sold primarily to hospitals and clinics across China through a network of distributors. The company's portfolio includes dry-powder injectables, liquid injectables, tablets, capsules, and granules — common delivery formats required by China's hospital-pharmacy formulary system. Its listed products address conditions such as hypertension, stroke recovery, and bacterial infections. Manufacturing takes place at a facility in Haikou that holds GMP certifications from Chinese regulators. The company has historically pursued growth through generic-drug approvals obtained when original Western drug patents expire in China, a strategy that leverages the country's comparatively shorter historical patent-enforcement timelines. It also develops products based on active pharmaceutical ingredients that have come off-patent abroad but still see demand in China. China Pharma Holdings is listed on the NYSE American exchange, a tier historically used by smaller-cap Chinese issuers before regulatory tightening. The company has faced challenges including delisting notices related to share-price minimums and delayed financial filings. In recent years, it has reported declining revenues as competition in China's generic-drug sector intensified after centralized procurement reforms. The company's 2023 communications emphasized a shift toward higher-margin specialty drugs and an effort to expand distribution networks into underserved rural markets. Structurally, the firm exemplifies the variable-interest-entity common among smaller Chinese companies listed in the U.S. that rely on contractual arrangements rather than direct equity ownership of onshore Chinese operating subsidiaries. This creates a legal separation between the Nevada-incorporated parent and the actual operating business in Hainan, a structure that has historically given U.S. investors uncertainty regarding asset-control rights in the event of a dispute.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Haikou
Corporate office
Haikou, Hainan, China
Sector focus
Frequently asked questions
What does China Pharma Holdings actually manufacture?
The company produces Western-medicine-based pharmaceuticals — primarily generic drugs — in tablet, capsule, injectable, and dry-powder formats. Public disclosures name products for hypertension, stroke, and bacterial infections. Manufacturing is concentrated at a GMP-certified facility in Haikou, Hainan province.
Why is this company listed on an American exchange?
China Pharma Holdings is incorporated in Nevada and accesses U.S. capital markets through a listing on NYSE American, a common path for smaller Chinese enterprises prior to the regulatory tightening of the early 2020s. The U.S.-listed entity controls its operating subsidiaries in China through contractual variable-interest-entity arrangements rather than direct equity ownership.
How does the company generate revenue?
Revenue comes principally from selling generic and off-patent pharmaceutical products to hospitals and clinics across China. The company relies on a network of third-party distributors. Profitability has been under pressure in recent years due to China's national volume-based procurement policies, which compress generic-drug pricing.
What is the company's current regulatory status with the NYSE?
The company has received multiple non-compliance notices from NYSE American in recent periods related to minimum share price and stockholders' equity thresholds. As public filings note, it continues to trade while pursuing compliance plans, but the listing status carries ongoing uncertainty.
Where is the physical manufacturing located?
Production takes place in Haikou, on China's island province of Hainan. This site has maintained GMP certification from Chinese regulatory authorities and is the operational core of the company, even as the legal parent is domiciled in Nevada.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: